Brain- and Heart-Type Fatty Acid-Binding Proteins in the Brain: Tissue Distribution and Clinical Utility

Pelsers, Maurice M.A.L.; Hanhoff, Thorsten; Voort, D. van der; Arts, Baer; Peters, Maarten; Ponds, Rudolf; Honig, Adriaan; Rudzinski, Wojtek; Spener, Friedrich; Kruijk, Jelle R. de; Twijnstra, A.; Hermens, Wim Th.; Menheere, P. P. C. A.; Glatz, Jan F. C.

doi:10.1373/clinchem.2003.030361

Cited by 109 publications

(100 citation statements)

References 45 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To obviate this, intracellular proteins such as FABPs orchestrate the movement of free fatty acids inside cells (26,50). FABPs are widely expressed in the central nervous system and the periphery (26)(27)(28)(29)(30)(31)(32) and may therefore serve as intracellular carriers for AEA in various tissues. In the brain, FABP3 and FABP5 are expressed in neurons while FABP7 is primarily localized in glial cells (27,46,51).…”

Section: Discussionmentioning

confidence: 99%

“…In the brain, FABP3 and FABP5 are expressed in neurons while FABP7 is primarily localized in glial cells (27,46,51). The wide distribution of FABPs in the mammalian brain (27,31) suggests that these proteins may coordinate the delivery of AEA to FAAH throughout the brain.…”

Section: Discussionmentioning

confidence: 99%

“…The FABP family of lipid carriers fits both of these criteria (26). These proteins are widely expressed in mammalian tissues, with three of its members, FABP3, FABP5, and FABP7, expressed in brain (26)(27)(28)(29)(30)(31)(32). In addition to fatty acids, these proteins carry other lipophilic ligands such as retinoic acid (33).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Identification of intracellular carriers for the endocannabinoid anandamide

Kaczocha¹,

Glaser

Deutsch³

2009

Proc. Natl. Acad. Sci. U.S.A.

305

332

View full text Add to dashboard Cite

The endocannabinoid anandamide (arachidonoyl ethanolamide, AEA) is an uncharged neuromodulatory lipid that, similar to many neurotransmitters, is inactivated through its cellular uptake and subsequent catabolism. AEA is hydrolyzed by fatty acid amide hydrolase (FAAH), an enzyme localized on the endoplasmic reticulum. In contrast to most neuromodulators, the hydrophilic cytosol poses a diffusional barrier for the efficient delivery of AEA to its site of catabolism. Therefore, AEA likely traverses the cytosol with the assistance of an intracellular carrier that increases its solubility and rate of diffusion. To study this process, AEA uptake and hydrolysis were examined in COS-7 cells expressing FAAH restricted to the endoplasmic reticulum, mitochondria, or the Golgi apparatus. AEA hydrolysis was detectable at the earliest measurable time point (

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of intracellular carriers for the endocannabinoid anandamide

Kaczocha¹,

Glaser

Deutsch³

2009

Proc. Natl. Acad. Sci. U.S.A.

305

332

View full text Add to dashboard Cite

show abstract

“…31 In a study to evaluate the clinical usefulness of B-FABP as a biomarker of brain injury, Pelsers et al 32 reported that B-FABP could be detected in the serum of 68% of the mild TBI patients examined. No B-FABP could be detected in the serum of healthy volunteer controls.…”

Section: Fatty Acid Binding Proteinsmentioning

confidence: 99%

Biomarkers for the Diagnosis, Prognosis, and Evaluation of Treatment Efficacy for Traumatic Brain Injury

et al. 2010

View full text Add to dashboard Cite

“…There are, however, other CSF markers that reflect other aspects of brain injuries such as white matter lesions and associated glial cell injury as well as neurodegenerative disease. These biomarkers include neurofilament light chain (NF-L), a marker of subcortical myelinated axons (Rosengren et al, 1996); myelin basic protein (MBP), a marker of oligodendrocytes (Olsson et al, 2011); the calcium-binding protein S100B, which is enriched in and might be secreted by astro-and oligodendrocytes (Schroeter et al, 2013); and heart-type fatty acid binding protein (H-FABP), which despite its name is a marker for cortical neurons (Pelsers et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Elevated Concentrations of Neurofilament Light Chain in the Cerebrospinal Fluid of Bipolar Disorder Patients

Jakobsson

Bjerke

Ekman

et al. 2014

Neuropsychopharmacol

View full text Add to dashboard Cite

Bipolar disorder (BD) is characterized by mood swings between manic and depressive states. The etiology and pathogenesis of BD is unclear, but many of the affected cognitive domains, as well as neuroanatomical abnormalities, resemble symptoms and signs of small vessel disease. In small vessel disease, cerebrospinal fluid (CSF) markers reflecting damages in different cell types and subcellular structures of the brain have been established. Hence, we hypothesized that CSF markers related to small vessel disease may also be applicable as biomarkers for BD. To investigate this hypothesis, we sampled CSF from 133 patients with BD and 86 healthy controls. The concentrations of neurofilament light chain (NF-L), myelin basic protein (MBP), S100B, and heart-type fatty acid binding protein (H-FABP) were measured in CSF and analyzed in relation to diagnosis, clinical characteristics, and ongoing medications. Hereby we found an elevation of the marker of subcortical axonal damage, NF-L, in bipolar subjects. We also identified positive associations between NF-L and treatment with atypical antipsychotics, MBP and lamotrigine, and H-FABP and lithium. These findings indicate axonal damage as an underlying neuropathological component of bipolar disorder, although the clinical value of elevated NF-L remains to be validated in follow-up studies. The associations between current medications and CSF brain injury markers might aid in the understanding of both therapeutic and adverse effects of these drugs.

show abstract

Brain- and Heart-Type Fatty Acid-Binding Proteins in the Brain: Tissue Distribution and Clinical Utility

Cited by 109 publications

References 45 publications

Identification of intracellular carriers for the endocannabinoid anandamide

Identification of intracellular carriers for the endocannabinoid anandamide

Biomarkers for the Diagnosis, Prognosis, and Evaluation of Treatment Efficacy for Traumatic Brain Injury

Elevated Concentrations of Neurofilament Light Chain in the Cerebrospinal Fluid of Bipolar Disorder Patients

Contact Info

Product

Resources

About